Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension

Advances in Therapy

Volumn 29, Issue 6, 2012, Pages 524-537

  Punzi, Henry A ^a   Lewin, Andrew ^b   Li, Wei ^c   Chavanu, Kathleen J ^c  

^a Punzi Medical Center   (United States)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

Ambulatory blood pressure; Blood pressure goal; Hypertension; Losartan potassium; Olmesartan medoxomil; Tolerability; Treatment na ve

Indexed keywords

LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OROPHARYNX PAIN; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 84866512636     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0029-5     Document Type: Article

References (24)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-50.
2. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404. (Pubitemid 35469393)
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-72. (Pubitemid 37430158)
4. Mancia G, De Backer G, Dominiczak A, et al Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87. (Pubitemid 46924065)
5. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens. 2007;9:187-95.
6. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12:203-8. (Pubitemid 28140291)
7. Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: A systematic review and metaanalysis. Pharmacotherapy. 2001;21:940-53. (Pubitemid 32747314)
8. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
9. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl. 1):S73-86. (Pubitemid 30409970)
10. Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol. 2007;151:952-62. (Pubitemid 47195538)
11. Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Br J Pharmacol. 1999;126:1057-65. (Pubitemid 29103724)
12. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68:1207-25. (Pubitemid 351822111)
13. Punzi HA. Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integr Blood Press Control. 2011;4:73-83.
14. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther. 2009;7:229-39.
15. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19:S21-32. (Pubitemid 32587656)
16. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283-91, 318.
17. Weir MR, Punzi HA, Flack JM, et al. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgrad Med. 2011;123:80-7.
18. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.
19. Zhu JR, Cai NS, Fan WH, et al. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Zhonghua xin xue guan bing za zhi. 2006;34:877-81. In Chinese.
20. Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54:427-36.
21. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit. 2001;6:63-72. (Pubitemid 32587662)
22. Punzi HA. Why ambulatory blood pressure monitoring? Am J Health Syst Pharm. 1998;55(Suppl. 3):S12-16. (Pubitemid 28525159)
23. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens. 2005;7:102-9.
24. Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657-64. (Pubitemid 29481484)